Pfizer selected Denmark as the site of the largest vaccine registry study ever undertaken, demonstrating how Europe can attract world-leading life sciences investment when the right conditions are in place. Beginning in 2024, Pfizer partnered with researchers at the Center for Translational Cardiology and Pragmatic Randomized Trials at Herlev-Gentofte Hospital in Copenhagen to assess whether its respiratory syncytial virus vaccine could reduce hospitalisations in adults. Denmark’s innovation-friendly environment, national digital mailbox eBoks and world-class health registries enabled researchers to invite almost the entire adult population to take part, helping recruit more than 500,000 participants. Study materials were made available online, allowing participants to provide informed consent from home, while health registries supported comprehensive tracking and analysis. This milestone shows how strong public-private collaboration and a supportive policy framework can help Europe deliver clinical research at scale and improve health outcomes for citizens. Read the full story on Invested in Europe.